{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:30:51Z","timestamp":1783607451400,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.lungcan.2025.108802","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:33:55Z","timestamp":1761089635000},"page":"108802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study"],"prefix":"10.1016","volume":"210","author":[{"given":"Christian","family":"Rolfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-6741","authenticated-orcid":false,"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-895X","authenticated-orcid":false,"given":"Jeffrey P.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Akerley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Naveh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108802_b0005","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2025.108802_b0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","article-title":"Tumor-Treating Fields: A fourth modality in cancer treatment","volume":"24","author":"Mun","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108802_b0015","doi-asserted-by":"crossref","first-page":"14073","DOI":"10.3390\/ijms232214073","article-title":"Tumor Treating Fields (TTFields) concomitant with immune checkpoint inhibitors are therapeutically effective in non-small cell lung cancer (NSCLC) in vivo model","volume":"23","author":"Barsheshet","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2025.108802_b0020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2025.108802_b0025","unstructured":"Novocure. Optune LUA\u2122: Instructions for use for non-small cell lung cancer (NSCLC). https:\/\/www.optuneluahcp.com\/nsclc\/instructions-for-use, 2024. (accessed: November 5, 2024)."},{"key":"10.1016\/j.lungcan.2025.108802_b0030","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): A randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0035","unstructured":"Novocure. Novocure\u2019s Optune Lua\u00ae Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer. https:\/\/www.novocure.com\/novocures-optune-luar-receives-ce-mark-approval-treatment-metastatic-non-small-cell-lung-cancer, 2025. (accessed: 7 May 2025, 2025)."},{"issue":"Suppl 6","key":"10.1016\/j.lungcan.2025.108802_b0040","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (Tumor Treating Fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","volume":"41","author":"Giladi","year":"2014","journal-title":"Semin. Oncol."},{"issue":"suppl_2","key":"10.1016\/j.lungcan.2025.108802_b0045","doi-asserted-by":"crossref","first-page":"II47","DOI":"10.1093\/annonc\/mdx091.053","article-title":"133P The influence of body composition on TTFields intensity in the lungs","volume":"28","author":"Weinberg","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0050","unstructured":"C.D. Fryar, M.D. Carroll, J. Afful. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960\u20131962 through 2017\u20132018. NCHS Health E-Stats. https:\/\/www.cdc.gov\/nchs\/data\/hestat\/obesity-adult-17-18\/obesity-adult.htm, 2020. (accessed: January 23, 2025)."},{"key":"10.1016\/j.lungcan.2025.108802_b0055","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/JTO.0b013e31829cf942","article-title":"Body mass index and its association with clinical outcomes for advanced non\u2013small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials","volume":"8","author":"Dahlberg","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0060","article-title":"BMI Classification Percentile And Cut Off Points","author":"Weir","year":"2024","journal-title":"In: StatPearls [Internet]. Treasure Island (FL). StatPearls Publishing"},{"key":"10.1016\/j.lungcan.2025.108802_b0065","unstructured":"ITIS Foundation. Morphed ViP3.x: Covering Population Variability. https:\/\/itis.swiss\/virtual-population\/virtual-population\/vip3-morphed\/, 2025. (accessed: March 20, 2025)."},{"key":"10.1016\/j.lungcan.2025.108802_b0070","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2025.108802_b0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0080","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2025.108802_b0085","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): A multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0090","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor Treating Fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.lungcan.2025.108802_b0095","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/cancers14061568","article-title":"Tumor Treating Fields concomitant with sorafenib in advanced hepatocellular cancer: Results of the HEPANOVA phase II study","volume":"14","author":"Gkika","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108802_b0100","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3390\/cancers14082020","article-title":"Feasibility of Tumor Treating Fields with pemetrexed and platinum-based chemotherapy for unresectable malignant pleural mesothelioma: Single-center, real-world data","volume":"14","author":"Kutuk","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2025.108802_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e15766","article-title":"Transducer array layout optimization for the treatment of pancreatic cancer using Tumor Treating Fields (TTFields) in the phase 3 PANOVA-3 trial","volume":"37","author":"Naveh","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0110","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1038\/s41598-023-30527-w","article-title":"Different correlation of body mass index with body fatness and obesity-related biomarker according to age, sex and race-ethnicity","volume":"13","author":"Jeong","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2025.108802_b0115","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2019.05.031","article-title":"Body mass index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: A pooled analysis of the International Lung Cancer Consortium","volume":"14","author":"Shepshelovich","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108802_b0120","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"NCD Risk Factor Collaboration, Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","year":"2024","journal-title":"Lancet"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T21:53:06Z","timestamp":1764798786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"alternative-id":["S0169500225006944"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108802","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108802"}}